1. Search Result
Search Result
Results for "

GCGR

" in MCE Product Catalog:

6

Inhibitors & Agonists

5

Peptides

Targets Recommended:
Cat. No. Product Name Target Research Areas
  • HY-P3506
    LY3437943

    GCGR GLP Receptor Metabolic Disease
    LY3437943 is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). LY3437943 inhibits for human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. LY3437943 can be used for the research of obesity.
  • HY-124622
    NNC-0640

    GCGR Metabolic Disease
    NNC-0640 is a potent human G-protein-coupled glucagon receptor (GCGR) negative allosteric modulator (NAM) with an IC50 of 69.2 nM.
  • HY-145632
    Pemvidutide

    GLP Receptor GCGR Metabolic Disease
    Pemvidutide is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research.
  • HY-P3613
    Oxyntomodulin (swine)

    GLP Receptor GCGR Metabolic Disease Neurological Disease
    Oxyntomodulin (swine) is a dual agonist for GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR), a peptide hormone released from the gut in post-prandial state. Oxyntomodulin (swine) suppresses appetite and reduces food intake.
  • HY-P2231
    Cotadutide

    MEDI0382

    GCGR Metabolic Disease
    Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D).
  • HY-P2231A
    Cotadutide acetate

    MEDI0382 acetate

    GCGR Metabolic Disease
    Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D).